FASL Antikörper (FITC)
-
- Target Alle FASL Antikörper anzeigen
- FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))
-
Reaktivität
- Human
-
Wirt
-
Hamster
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser FASL Antikörper ist konjugiert mit FITC
-
Applikation
- Flow Cytometry (FACS)
- Spezifität
- This antibody reacts with Fas Ligand.
- Kreuzreaktivität (Details)
- Species reactivity (tested):Human
- Aufreinigung
- Protein A agarose
- Immunogen
- Recombinant human Fas Ligand
- Klon
- GE 4-90
- Isotyp
- IgG
- Top Product
- Discover our top product FASL Primärantikörper
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS, 0.09 % NaN3, 1 % BSA
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C
- Informationen zur Lagerung
- Store at 2 - 8 °C.
-
- Target
- FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))
- Andere Bezeichnung
- CD178 / Fas Ligand (FASL Produkte)
- Hintergrund
- Fas ligand (FasL/CD178/CD95L) is a type II-membrane protein, belonging the tumor necrosis factor (TNF)/nerve growth factor (NGF) family. It is known that engagement of Fas (receptor of FasL) by FasL causes apoptotic cell death. FasL is predominantly expressed in activated T lymphocytes and Natural Killer (NK) cells and expressed in the tissues of the immune-privilege sites such as the testis and eye. On the other hand, Fas is expressed in various tissues with abundant expression in the thymus, liver, heart, and kidney. Furthermore, a variety of cancers such as melanomas were found to express FasL in addition to Fas. It is said that, Fas/FasL system is involved in the deletion of dangerous activated or autoreactive T and B cells, and in tern play a role in human diseases such as fulminant hepatitis, AIDS, cancers and other diseases involving CTL-induced tissue destruction. Furthermore, FasL can be used as an immune-suppressive agent. Rejection of transplants is mediated by activated T cells that may express functional Fas. If a transplanted tissue is engineered to express FasL or is co-transplanted with FasL-expressing cells, the transplant may be tolerated.Synonyms: APT1LG1, APTL, Apoptosis antigen ligand, CD95L protein, FASL, FASLG, Fas antigen ligand, TNFSF6, Tumor necrosis factor ligand superfamily member 6
- Gen-ID
- 356
- NCBI Accession
- NP_000630
- UniProt
- P48023
- Pathways
- Apoptose, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity
-